Investigating new treatments and prevention methods for infectious diseases.
Official title: Early Phase Clinical Trial Units
Funded at Dynport Vaccine Company, LLC · NIH-10655855 · Data updated 2026-11-12
This study is looking for people to try out new treatments and prevention methods for infectious diseases, so if you're interested in helping find better ways to fight these illnesses, this could be a great opportunity for you!
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dynport Vaccine Company, LLC NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | January 14, 2022 |
| Project end | January 13, 2032 |
| Funding year | 2022 |
| Award (this year) | $172,910 |
| NIH project number | 75N93022D00016-0-759302200001-1 |
| Project ID | NIH-10655855 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals diagnosed with infectious diseases who are seeking new treatment options.
✕Less likely to help
Patients with non-infectious diseases or those who do not meet the specific criteria for the trials may not benefit from this research.
What this research studies
This research focuses on early phase clinical trial units that explore new agents aimed at treating and preventing infectious diseases. The approach involves implementing interventional clinical trials, which means that patients may receive new therapies or preventive measures that are currently not available. Patients participating in these trials will be closely monitored to assess the effectiveness and safety of these new treatments. The research aims to gather valuable data that could lead to improved strategies for managing infectious diseases.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments and prevention strategies for infectious diseases.
How similar studies have gone: Other research in early phase clinical trials for infectious diseases has shown promise, indicating that this approach can lead to significant advancements in treatment.
Where this research is happening
-
Dynport Vaccine Company, LLC
Frederick, United States Active
Researchers
- Principal investigator: Saviolakis, George — Dynport Vaccine Company, LLC
- Study coordinator: Saviolakis, George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.